Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at German Cancer Research Center, Division of Cellular Immunology report research in cancer vaccines
May 20th, 2008
A new study, 'An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins,' is now available. "T cell costimulation has great therapeutic potential if it can be optimized and controlled. To achieve this, we engineered T cell-activating fusion proteins and immunocytokines that specifically attach to viral antigens of a virus-infected tumor vaccine," scientists in Heidelberg, Germany report. "We employed the avian Newcastle Disease Virus because this agent is highly efficient for human tumor cell infection, and leads to introduction of viral hemagglutinin-neuraminidase (HN) molecules at the tumor cell surface. Here, we...
Source: Cancer Weekly (2008-05-20)
|
